The final session at BIG was entitled Turning Pharma on its Head: The Next Big Thing. There was discussion of particular technologies and immune therapies but again one of the conundrums was how to bring to market pre-symptomatic therapies, the difficulty of diagnosing wellness and to posit when wellness will progress to disease. Commercial models are there in other sectors for a 'maintenance' approach to health and there are some interesting examples within healthcare (eg the use of statins). However, if we are going to have a successful paradigm shift from a largely reactive healthcare system to a preventative one, collective and cross-industry dialogue is needed. Scientists, investors, regulators, reimbursement agencies, HCPs, patients, and dare I say it lawyers(1) need to come together and develop constructive models.Much food for thought as I spend my last few hours on the beach in Aruba!
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-10-08-10-50-28-575-67050e74c71f57809f6d0411.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2025-02-05-11-45-56-829-67a34f74966bf3c993454c6a.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2025-02-04-16-21-29-274-A27003_Life_Sciences_January_2025_Brochure_English_V1_afterchange_thumbnail_1.png)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2025-01-24-09-38-32-700-67935f98312d8a93f10c9c08.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2025-01-10-14-30-15-393-67812ef70155f36f24518bf9.jpg)
